• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Prophylaxis with Tixagevimab/Cilgavimab in chronic lymphocytic leukaemia, a case control study.

作者信息

Guarnera Luca, Tiravanti Ilaria, Guiducci Arianna, Coppola Luigi, Marinoni Massimiliano, Nunzi Andrea, Laureana Roberta, Cardillo Lucia, Esposito Fabiana, Secchi Roberto, Buzzatti Elisa, Paterno Giovangiacinto, Pupo Livio, Sarmati Loredana, Gattei Valter, Venditti Adriano, Postorino Massimiliano, Del Principe Maria Ilaria

机构信息

Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.

Department of Translational Hematology & Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, 44114, USA.

出版信息

Ann Hematol. 2024 Sep;103(9):3831-3833. doi: 10.1007/s00277-024-05815-8. Epub 2024 Jul 19.

DOI:10.1007/s00277-024-05815-8
PMID:39026027
Abstract
摘要

相似文献

1
Prophylaxis with Tixagevimab/Cilgavimab in chronic lymphocytic leukaemia, a case control study.替沙格韦单抗/西加韦单抗在慢性淋巴细胞白血病中的预防作用：一项病例对照研究
Ann Hematol. 2024 Sep;103(9):3831-3833. doi: 10.1007/s00277-024-05815-8. Epub 2024 Jul 19.
2
Efficacy and safety of tixagevimab/cilgavimab as passive immunisation against COVID-19 infections in patients with hematological malignancies.替沙格韦单抗/西加韦单抗作为 COVID-19 感染被动免疫疗法用于血液系统恶性肿瘤患者的疗效和安全性。
Ann Hematol. 2024 Jun;103(6):2123-2131. doi: 10.1007/s00277-024-05671-6. Epub 2024 Mar 2.
3
Pre-exposure prophylaxis with tixagevimab/cilgavimab in patients with chronic lymphocytic leukaemia treated with targeted agents.在接受靶向药物治疗的慢性淋巴细胞白血病患者中使用替沙格韦单抗/西加韦单抗进行暴露前预防。
Br J Haematol. 2023 May;201(3):564-567. doi: 10.1111/bjh.18701. Epub 2023 Feb 22.
4
Tixagevimab/cilgavimab (AZD7442/Evusheld) prevent from COVID19 in patients with hematologic malignancies under active chemotherapy.替沙格韦单抗/西加韦单抗（AZD7442/埃武尤单抗）预防正在接受积极化疗的血液恶性肿瘤患者的 COVID19。
Ann Hematol. 2024 Jul;103(7):2533-2539. doi: 10.1007/s00277-024-05769-x. Epub 2024 Apr 28.
5
Real-world clinical outcomes of tixagevimab/cilgavimab in the Omicron outbreak in China: baseline characteristics and interim analysis of the CLEAR study.在中国奥密克戎疫情期间替沙格韦单抗/西加韦单抗的真实世界临床结局：CLEAR 研究的基线特征和中期分析。
Virol J. 2024 Oct 24;21(1):262. doi: 10.1186/s12985-024-02509-5.
6
COSMIC, chemotherapy plus ofatumumab at standard or mega-dose in chronic lymphocytic leukaemia, a phase II randomised study.COSMIC研究：慢性淋巴细胞白血病中标准剂量或大剂量化疗联合奥法木单抗的II期随机研究
Br J Haematol. 2021 Aug;194(3):646-650. doi: 10.1111/bjh.17526. Epub 2021 May 24.
7
A phase I-II clinical trial of the anti-CD74 monoclonal antibody milatuzumab in frail patients with refractory chronic lymphocytic leukaemia: A patient based approach.抗CD74单克隆抗体米拉妥珠单抗用于难治性慢性淋巴细胞白血病体弱患者的I-II期临床试验：基于患者的研究方法
Br J Haematol. 2018 Jul;182(1):125-128. doi: 10.1111/bjh.14726. Epub 2017 May 3.
8
Safety and efficacy of tixagevimab/cilgavimab for pre-exposure prophylaxis in kidney transplant recipients: a multicenter retrospective cohort study.替沙格韦单抗/西加韦单抗用于肾移植受者暴露前预防的安全性和有效性：一项多中心回顾性队列研究。
J Nephrol. 2024 Jul;37(6):1539-1550. doi: 10.1007/s40620-024-01889-9. Epub 2024 May 23.
9
Tixagevimab/Cilgavimab does not prevent COVID-19 in patients with multiple sclerosis and related disorders on B-cell depleting therapies.替沙格韦单抗/西加韦单抗不能预防接受 B 细胞耗竭疗法的多发性硬化症及相关疾病患者的 COVID-19。
Mult Scler Relat Disord. 2024 Jul;87:105680. doi: 10.1016/j.msard.2024.105680. Epub 2024 May 12.
10
Prophylaxis with tixagevimab/cilgavimab is associated with lower COVID-19 incidence and severity in patients with autoimmune diseases.替沙格韦单抗/西加韦单抗预防可降低自身免疫性疾病患者 COVID-19 的发病率和严重程度。
Rheumatology (Oxford). 2024 May 3;63(6):1632-1638. doi: 10.1093/rheumatology/kead449.

本文引用的文献

1
Efficacy of tixagevimab-cilgavimab in preventing SARS-CoV-2 for patients with B-cell malignancies.替沙格韦单抗-西加韦单抗预防 B 细胞恶性肿瘤患者感染 SARS-CoV-2 的疗效。
Blood. 2023 Jan 12;141(2):200-203. doi: 10.1182/blood.2022018283.
2
Patients with CLL have a lower risk of death from COVID-19 in the Omicron era.在奥密克戎时代，CLL 患者因 COVID-19 而死亡的风险较低。
Blood. 2022 Aug 4;140(5):445-450. doi: 10.1182/blood.2022016147.